Engineered immune cells aim to tame autoimmune diseases
NCT ID NCT07586267
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusion after a short chemotherapy-like prep. The main goals are to check safety and see if the disease improves within 90 days. About 15 adults with hard-to-treat autoimmune conditions will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED SYSTEMIC VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310052, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can skin biopsies unlock new treatments for scleroderma?
- Could a skin patch ease stomach pain in scleroderma?
- Could a painless microneedle pad ease Raynaud's in scleroderma?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Mapping the Real-World treatment landscape for IgA nephropathy